SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-010574
Filing Date
2023-04-04
Accepted
2023-04-04 16:06:18
Documents
13
Period of Report
2023-04-03
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngm-20230403.htm   iXBRL 8-K 38697
2 EX-99.1 ngm-20230403xexx991.htm EX-99.1 11747
  Complete submission text file 0001628280-23-010574.txt   185524

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20230403.xsd EX-101.SCH 1881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20230403_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20230403_pre.xml EX-101.PRE 12495
7 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20230403_htm.xml XML 4128
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 23797341
SIC: 2834 Pharmaceutical Preparations